Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway
Authors:
- 1 May 2010
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 69 (5) , 931-932
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexateRheumatology, 2009
- Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolismEuropean Journal of Clinical Pharmacology, 2008
- A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent‐onset rheumatoid arthritisArthritis & Rheumatism, 2007
- Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritisArthritis & Rheumatism, 2006
- Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent‐onset rheumatoid arthritisArthritis & Rheumatism, 2006
- Risk genotypes in folate‐dependent enzymes and their association with methotrexate‐related side effects in rheumatoid arthritisArthritis & Rheumatism, 2006
- Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritisArthritis & Rheumatism, 2004
- Validation of rheumatoid arthritis improvement criteria that include simplified joint countsArthritis & Rheumatism, 1998